Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer

被引:140
作者
Hovens, Guido C.
Stokkel, Marcel P.
Kievit, Job
Corssmit, Eleonora P.
Pereira, Alberto M.
Romijn, Johannes A.
Smit, Johannes W. A.
机构
[1] Leiden Univ, Med Ctr, Dept Endocrinol, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Metab Dis, NL-2300 RC Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Nucl Med, NL-2300 RC Leiden, Netherlands
[4] Leiden Univ, Med Ctr, Dept Med Decis Making, NL-2300 RC Leiden, Netherlands
关键词
D O I
10.1210/jc.2006-2566
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The relation between serum TSH levels and risk for recurrence or thyroid carcinoma-related death in patients with differentiated thyroid carcinoma has only been studied to a limited extent. Design: We conducted a single-center observational study in 366 consecutive patients with differentiated thyroid carcinoma, who had all been treated according to the same protocol for initial therapy and follow-up. Median duration of follow-up was 8.85 yr. Methods: The relation between summarizing variables of unstimulated serum TSH concentrations (25th, 50th, and 75th percentiles, the percentage of suppressed and unsuppressed TSH values) and risk for recurrence or thyroid carcinoma-related death was analyzed by Cox survival analyses in patients with at least four TSH measurements. Results: In Cox regression analysis, we found a positive association between serum TSH concentrations and risk for thyroid carcinoma-related death and relapse, even in initially cured patients. The median of the individual TSH concentrations was the best indicator for thyroid carcinoma-related death (hazard ratio 2.03; confidence interval 1.22-3.37) and relapse (hazard ratio 1.41; confidence interval 1.03-1.95). A threshold of 2 mU/liter differentiated best between relapse-free survival and thyroid carcinoma-related death or relapse. Conclusion: Our study supports current guidelines, which advise to aim at TSH levels in the low normal range in cured low-risk patients, whereas TSH levels should be suppressed in noncured or high-risk patients.
引用
收藏
页码:2610 / 2615
页数:6
相关论文
共 24 条
  • [1] [Anonymous], TNM CLASSIFICATION M
  • [2] BALME HW, 1954, LANCET, V1, P812
  • [3] Thyroid-hormone therapy and thyroid cancer: a reassessment
    Biondi, B
    Filetti, S
    Schlumberger, M
    [J]. NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2005, 1 (01): : 32 - 40
  • [4] Subclinical hyperthyroidism: clinical features and treatment options
    Biondi, B
    Palmieri, EA
    Klain, M
    Schlumberger, M
    Filetti, S
    Lombardi, G
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 152 (01) : 1 - 9
  • [5] HUMAN THYROID-CANCER - MEMBRANE THYROTROPIN BINDING AND ADENYLATE-CYCLASE ACTIVITY
    CARAYON, P
    THOMASMORVAN, C
    CASTANAS, E
    TUBIANA, M
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1980, 51 (04) : 915 - 920
  • [6] CHARACTERIZATION OF THE THYROTROPIN RECEPTOR-ADENYLATE CYCLASE SYSTEM IN NEOPLASTIC HUMAN THYROID-TISSUE
    CLARK, OH
    GEREND, PL
    GORETZKI, P
    NISSENSON, RA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 57 (01) : 140 - 147
  • [7] Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry
    Cooper, DS
    Specker, B
    Ho, M
    Sperling, M
    Ladenson, PW
    Ross, DS
    Ain, KB
    Bigos, ST
    Brierley, JD
    Haugen, BR
    Klein, I
    Robbins, J
    Sherman, SI
    Taylor, T
    Maxon, HR
    [J]. THYROID, 1998, 8 (09) : 737 - 744
  • [8] ENDOCRINE DEPENDENCY OF PAPILLARY CARCINOMAS OF THYROID
    CRILE, G
    [J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1966, 195 (09): : 721 - &
  • [9] THYROID-CARCINOMA WITH SPINAL-CORD COMPRESSION
    GOLDBERG, LD
    DITCHEK, NT
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1981, 245 (09): : 953 - 954
  • [10] Goretzki P E, 1990, Recent Results Cancer Res, V118, P48